Find, compare & contact
Sodium dihydrogenphosphate dihydrate API Manufacturers & Suppliers

Looking for Sodium dihydrogenphosphate dihydrate API 13472-35-0?

Description:

Here you will find a list of producers, manufacturers and distributors of Sodium dihydrogenphosphate dihydrate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Sodium dihydrogenphosphate dihydrate 

Synonyms:

Sodium dihydrogen phosphate dihydrate , Monosodium phosphate dihydrate , 10028-24-7  

Cas Number:

13472-35-0 

DrugBank number:

DBSALT001970 

Unique Ingredient Identifier:

5QWK665956

Sodium dihydrogenphosphate dihydrate is a type of Calcium regulators

Calcium regulators are a vital subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs) used in the field of medicine. These compounds play a crucial role in maintaining the balance of calcium levels within the body. Calcium is an essential mineral that participates in numerous physiological processes, including muscle contraction, nerve transmission, and bone health.

Pharmaceutical APIs classified as calcium regulators are designed to modulate the levels of calcium in the body, either by increasing or decreasing its concentration as needed. These APIs act by targeting specific mechanisms involved in calcium regulation, such as calcium channels, transporters, or enzymes.

Calcium regulators find application in the treatment of various medical conditions. For instance, drugs that promote calcium absorption or enhance bone mineral density can be employed to manage osteoporosis, a condition characterized by weak and brittle bones. Conversely, medications that inhibit calcium channels or reduce calcium levels are used in the treatment of conditions like hypertension or cardiac arrhythmias.

The development of calcium regulators involves extensive research and rigorous testing to ensure their safety and efficacy. Pharmaceutical companies invest significant resources in the discovery, synthesis, and optimization of these APIs. Additionally, regulatory authorities closely monitor the production and distribution of calcium regulators to ensure compliance with stringent quality standards.

In summary, calcium regulators are a specialized category of pharmaceutical APIs that play a crucial role in maintaining calcium balance within the body. These compounds are integral to the treatment of various medical conditions and require rigorous research and testing to ensure their effectiveness and safety.

Sodium dihydrogenphosphate dihydrate (Calcium regulators), classified under Metabolic Bone Disease Agents

Metabolic Bone Disease Agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) that are specifically designed to treat and manage conditions related to the bones and their metabolism. These agents play a crucial role in the treatment of various metabolic bone diseases, including osteoporosis, Paget's disease, and rickets.

The primary function of Metabolic Bone Disease Agents is to regulate bone remodeling and maintain bone health. They achieve this by targeting specific pathways involved in bone metabolism, such as osteoclast and osteoblast activity, calcium regulation, and vitamin D metabolism.

These APIs are commonly used in the development of medications, including oral tablets, injectables, and topical formulations, for the effective treatment of metabolic bone diseases. They are carefully formulated to optimize their pharmacokinetic and pharmacodynamic properties, ensuring maximum efficacy and minimal side effects.

Metabolic Bone Disease Agents encompass a range of substances, including bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, and vitamin D analogs. These APIs act through different mechanisms to address specific aspects of bone health, such as inhibiting bone resorption, promoting bone formation, or regulating calcium levels.

In conclusion, Metabolic Bone Disease Agents are a vital category of pharmaceutical APIs used in the development of medications for the treatment and management of various metabolic bone diseases. These agents target specific pathways involved in bone metabolism to regulate bone remodeling, enhance bone health, and alleviate the symptoms associated with these conditions.

• Fujifilm Wako Pure Chemical Corporation from Japan, product country of origin Japan
• Caesar & Loretz GmbH (CAELO) from Germany, product country of origin Unknown

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.